{
  "paper_metadata": {
    "pmid": "30547773",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on a BRCA2 somatic mutation found in a case of locally advanced rectal cancer."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.2231C>A",
      "protein_notation": "p.S744*",
      "genomic_position": null,
      "clinical_significance": "somatic mutation",
      "patients": {
        "count": 1,
        "demographics": "25-year-old male",
        "phenotype": "locally advanced rectal cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": 25,
          "age_at_onset": null,
          "age_at_diagnosis": 25,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "locally advanced rectal cancer with complete pathological response to neoadjuvant chemotherapy",
          "evidence_sentence": "We report a case of a 25-year-old male with LARC treated with neoadjuvant FOLFOX chemotherapy, and experienced a pCR."
        }
      ],
      "functional_data": {
        "summary": "The presence of BRCA2 somatic mutation was associated with high mutation loads and an excellent response to oxaliplatin-based chemotherapy.",
        "assays": [
          "next-generation sequencing"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "case report",
      "source_location": "Results, paragraph 4",
      "additional_notes": "This is the first report of a BRCA2 mutant LARC that demonstrated significant benefit from FOLFOX neoadjuvant treatment.",
      "key_quotes": [
        "To our knowledge, this is the first report of BRCA2 mutant LARC that demonstrated significant benefit from FOLFOX neoadjuvant treatment.",
        "The presence of BRCA2 somatic mutation (c.2231C>A p.S744*) was observed."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Only one BRCA2 variant was reported in the paper."
  }
}